ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Alpha Cognition Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.50+0.31 (+3.79%)
Close on Oct 19, 2026
- Market cap
- $185.08M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.70 (+25.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Alpha Cognition Inc. reported revenue of $15.26M for the twelve months to Jun 30, 2026. Free cash flow was -$31.18M.
Revenue
$15.26M
TTM Q2 2026
Operating income
-$29.09M
TTM Q2 2026
Free cash flow
-$31.18M
TTM Q2 2026
EPS, diluted
-$1.18
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $185.08M
- P/E ratio
- –
- Price to sales
- 12.13
- Price to book
- 3.49
- Dividend yield
- –
- Free cash flow yield
- -16.84%
Fundamentals
- Revenue
- $15.26M
- Net income
- -$23.44M
- EPS, diluted
- -$1.18
- Free cash flow
- -$31.18M
- Book value per share
- $2.43
- Diluted shares
- 22M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$15.26M
Gross profit
$14.15M
Operating income
-$29.09M
Net income
-$23.44M
EPS, diluted
–
Free cash flow
-$31.18M
Reported periodTrailing twelve months